ハイドロゲルベースのドラッグデリバリーシステムの世界市場規模は、2028年までに106億USドルに達する見込みです。この市場は、2021年から2028年にかけて、7.5%のCAGRで拡大すると予想されています。ハイドロゲルは、組み込まれた薬物の放出を空間的・時間的に制御するのに役立ちます。したがって、多くの治療分野で放出制御型ドラッグデリバリーシステムの需要が急増していることが、予測期間中の市場成長に貢献すると期待される主な要因です。
ハイドロゲルベースのドラッグデリバリーシステムは、治療薬を標的部位に直接、かつ持続的に送達します。これにより、患者や処方者にとって、有効性の向上、副作用の軽減、投与量の削減などの有益な結果が得られます。ハイドロゲルベースのドラッグデリバリーシステムは魅力的であり、腫瘍学、疼痛管理、免疫学、心臓学、創傷管理など多くの医学分野で使用されています。
ハイドロゲルのユニークな物理的特性は、ドラッグデリバリーアプリケーションでの使用に関心を集めています。ハイドロゲルの多孔性と薬物搭載量は、架橋密度を変更することで調整でき、これにより、大きな薬物分子を分解から守り、半減期を延ばすことができる。ハイドロゲルシステムを用いたインスリンの経口投与については、多くの研究が行われています。注射タイプのインスリンでは、患者のコンプライアンスの問題が頻繁に報告されているため、このような革新的な技術は、糖尿病治療市場において破壊的な技術となることが期待されています。
ハイドロゲルベースのドラッグデリバリーシステムに特化した数多くの臨床研究が進行中であり、様々なハイドロゲル技術がバイオメディカル用途で既に規制当局の承認を受けています。しかし、明確な規制ガイドラインがないこと、化学的性質、複雑な製造および制御パラメータ、実用的な適応性などの技術的課題は、ドラッグデリバリー用途での導入を成功させるための大きな障害となっています。例えば、ハイドロゲルの製造は複雑で、ハイドロゲルの種類によって大きく異なります。
目次
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Polymer origin
1.1.2. Delivery route
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.3.5.1. Data for primary interviews in North America
1.3.5.2. Data for primary interviews in Europe
1.3.5.3. Data for primary interviews in Asia Pacific
1.3.5.4. Data for primary interviews in Latin America
1.3.5.5. Data for Primary interviews in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Regional outlook
2.3. Competitive Insights
Chapter 3. Hydrogel Based Drug Delivery Systems Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.3.1. Reimbursement framework
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.2. Market restraint analysis
3.4.3. Market opportunity analysis
3.4.4. Market challenge analysis
3.5. Hydrogel Based Drug Delivery Systems Market Analysis Tools
3.5.1. Industry analysis - Porter’s
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic landscape
3.5.3. Major deals &strategic alliances analysis
3.5.4. Market entry strategies
Chapter 4. Global Hydrogel Based Drug Delivery Systems Market: Polymer Origin Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. Natural
4.1.2. Synthetic
4.1.3. Hybrid
4.2. Global Hydrogel Based Drug Delivery Systems Market Share, 2020&2028
4.3. Segment Dashboard
4.4. Global Hydrogel Based Drug Delivery Systems Market by Polymer Origin Outlook
4.5. Market Size & Forecasts and Trend Analyses, 2020 to 2028 for the following
4.5.1. Natural
4.5.1.1. Natural market, 2016 - 2028 (Revenue, USD Million)
4.5.2. Synthetic
4.5.2.1. Synthetic Market, 2016 - 2028 (Revenue, USD Million)
4.5.3. Hybrid
4.5.3.1. Hybrid Market, 2016 - 2028 (Revenue, USD Million)
Chapter 5. Global Hydrogel Based Drug Delivery Systems Market: Delivery Route Estimates & Trend Analysis
5.1. Definitions and Scope
5.1.1. Subcutaneous
5.1.2. Ocular
5.1.3. Oral Cavity
5.1.4. Topical
5.1.5. Other
5.2. Global Hydrogel Based Drug Delivery Systems Market Share, 2020&2028
5.3. Segment Dashboard
5.4. Global Hydrogel Based Drug Delivery Systems Market by Delivery Route Outlook
5.5. Market Size & Forecasts and Trend Analyses, 2020 to 2028 for the following
5.5.1. Subcutaneous
5.5.1.1. Subcutaneous market, 2016 - 2028 (Revenue, USD Million,)
5.5.2. Ocular
5.5.2.1. Ocular Market, 2016 - 2028 (Revenue, USD Million)
5.5.3. Oral Cavity
5.5.3.1. Oral Cavity Market, 2016 - 2028 (Revenue, USD Million)
5.5.4. Topical
5.5.4.1. Topical Market, 2016 - 2028 (Revenue, USD Million)
5.5.5. Other
5.5.5.1. Other Market, 2016 - 2028 (Revenue, USD Million)
Chapter 6. Global Hydrogel Based Drug Delivery Systems Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2020&2028
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. Regional Market Share and Leading Players, 2021
6.4.1. North America
6.4.2. Europe
6.4.3. Asia Pacific
6.4.4. Latin America
6.4.5. Middle East and Africa
6.5. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
6.5.1. North America
6.5.2. Europe
6.5.3. Asia Pacific
6.5.4. Latin America
6.5.5. Middle East and Africa
6.6. Market Size, & Forecasts, Volume and Trend Analysis, 2016 to 2028:
6.7. North America
6.7.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.7.2. U.S.
6.7.2.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.7.3. Canada
6.7.3.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.8. Europe
6.8.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.8.2. U.K.
6.8.2.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.8.3. Germany
6.8.3.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.8.4. France
6.8.4.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.8.5. Italy
6.8.5.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.8.6. Spain
6.8.6.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.9. Asia Pacific
6.9.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.9.2. Japan
6.9.2.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.9.3. China
6.9.3.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.9.4. India
6.9.4.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.9.5. South Korea
6.9.5.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.9.6. Thailand
6.9.6.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.10. Latin America
6.10.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.10.2. Brazil
6.10.2.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.10.3. Mexico
6.10.3.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.10.4. Argentina
6.10.4.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.11. MEA
6.11.1. South Africa
6.11.1.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.11.2. Saudi Arabia
6.11.2.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.11.3. UAE
6.11.3.1. Market estimates and forecast, 2016 - 2028(Revenue, USD
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.2.1. Innovators
7.2.2. Market leaders
7.2.3. Emerging players
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2020
7.4. Public Companies
7.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
7.4.2. Company market share/ranking, by region
7.4.3. Competitive dashboard analysis
7.4.3.1. Market differentiators
7.4.3.2. Synergy analysis: major deals and strategic alliances
7.5. Private Companies
7.5.1. List of key emerging companies/technology disruptors/innovators
7.5.2. Funding outlook
7.5.3. Regional network map
7.5.4. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
7.5.5. Supplier ranking
7.5.6. Key company profiled
7.5.7. Ferring B.V.
7.5.7.1. Company overview
7.5.7.2. Financial performance
7.5.7.3. Product benchmarking
7.5.7.4. Strategic initiatives
7.5.8. Endo International plc
7.5.8.1. Company overview
7.5.8.2. Financial performance
7.5.8.3. Product benchmarking
7.5.8.4. Strategic initiatives
7.5.9. Akorn, Incorporated
7.5.9.1. Company overview
7.5.9.2. Financial performance
7.5.9.3. Product benchmarking
7.5.9.4. Strategic initiatives
7.5.10. Tolmar Pharmaceuticals, Inc
7.5.10.1. Company overview
7.5.10.2. Financial performance
7.5.10.3. Product benchmarking
7.5.10.4. Strategic initiatives
7.5.11. GALDERMA
7.5.11.1. Company overview
7.5.11.2. Financial performance
7.5.11.3. Product benchmarking
7.5.11.4. Strategic initiatives
7.5.12. Blairex Laboratories, Inc.
7.5.12.1. Company overview
7.5.12.2. Financial performance
7.5.12.3. Product benchmarking
7.5.12.4. Strategic initiatives
7.5.13. Johnson & Johnson
7.5.13.1. Company overview
7.5.13.2. Financial performance
7.5.13.3. Product benchmarking
7.5.13.4. Strategic initiatives
7.5.14. Bausch and Lomb
7.5.14.1. Company overview
7.5.14.2. Financial performance
7.5.14.3. Product benchmarking
7.5.14.4. Strategic initiatives
7.5.15. Medtronic
7.5.15.1. Company overview
7.5.15.2. Financial performance
7.5.15.3. Product benchmarking
7.5.15.4. Strategic initiatives
7.5.16. Ocular Therapeutix, Inc.
7.5.16.1. Company overview
7.5.16.2. Financial performance
7.5.16.3. Product benchmarking
7.5.16.4. Strategic initiatives
